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Mutations in several genes encoding ion channels can cause the long-QT (LQT)
syndrome with cardiac arrhythmias, syncope and sudden death. Recently, mutations in
some of these genes were also identified to cause epileptic seizures in these patients, and
the sudden unexplained death in epilepsy (SUDEP) was considered to be the pathologic
overlap between the two clinical conditions. For LQT-associated KCNQ1mutations, only
few investigations reported the coincidence of cardiac dysfunction and epileptic seizures.
Clinical, electrophysiological and genetic characterization of a large pedigree (n = 241
family members) with LQT syndrome caused by a 12-base-pair duplication in exon 8 of
the KCNQ1 gene duplicating four amino acids in the carboxyterminal KCNQ1 domain
(KCNQ1dup12; p.R360_Q361dupQKQR, NM_000218.2, hg19). Electrophysiological
recordings revealed no substantial KCNQ1-like currents. The mutation did not exhibit a
dominant negative effect on wild-type KCNQ1 channel function. Most likely, the mutant
protein was not functionally expressed and thus not incorporated into a heteromeric
channel tetramer. Many LQT family members suffered from syncopes or developed
sudden death, often after physical activity. Of 26 family members with LQT, seizures were
present in 14 (LQTplus seizure trait). Molecular genetic analyses confirmed a causative
role of the novel KCNQ1dup12 mutation for the LQT trait and revealed a strong link
also with the LQTplus seizure trait. Genome-wide parametric multipoint linkage analyses
identified a second strong genetic modifier locus for the LQTplus seizure trait in the
chromosomal region 10p14. The linkage results suggest a two-locus inheritance model
for the LQTplus seizure trait in which both the KCNQ1dup12 mutation and the 10p14
risk haplotype are necessary for the occurrence of LQT-associated seizures. The data
strongly support emerging concepts that KCNQ1 mutations may increase the risk of
epilepsy, but additional genetic modifiers are necessary for the clinical manifestation of
epileptic seizures.
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INTRODUCTION
Prolonged QT intervals are the diagnostic hallmark of inherited
long-QT (LQT) syndromes which comprise a growing number
of mutations in ion channels, with the gene encoding the
voltage-gated potassium channel KCNQ1 (Kv7.1) being the most
common LQT gene (OMIM #192500: LQT1) (1). LQT syndrome
by KCNQ1 mutations has long been considered as a cardiac
disease with the risk of ventricular arrhythmias and sudden
cardiac death, resulting from prolongation of the cardiac action
potential. However, patients with LQT syndrome can also present
with epileptic seizures which suggested that the underlying
genetic cause might be relevant for both phenotypes (2). In
patients with LQT1 syndrome due to KCNQ1mutations, clinical
seizures were consistently observed (3, 4). Indeed, recent research
identified the dual expression of KCNQ1 in the heart and in the
brain with neurons in forebrain networks and brainstem nuclei
expressing the highest levels (5). The same study used a mouse
model carrying a human KCNQ1 knock-in mutation which
resulted not only in cardiac arrhythmias but also in seizures
and sudden unexpected death in epilepsy (SUDEP). The model
reflects emerging evidence from clinical cohorts of patients with
LQT syndrome in which there is an increased association with
epilepsy and seizure-like phenotypes, in particular in the related
LQT disease with mutations in the gene encoding the voltage-
gated potassium channel KCNH2 (Kv11.1, hERG1) (6, 7).
More than 10 years ago, we have identified a family of Kurdish
descent with a novel mutation in theKCNQ1 gene, consisting of a
12-base-pair duplication (KCNQ1dup12) in exon 8 (8). However,
it was unclear whether this mutation is causing functional effects,
thus plausibly explaining the clinical symptoms. Remarkably,
identification of the KCNQ1 mutation in the index patients was
antedated by a several years’ history of epileptic seizures and
treatment with anti-epileptic drugs including carbamazepine.
Although suggestive, at that time it was an unsolved question
whether KCNQ1 mutations may cause both, cardiac symptoms
and epileptic seizures. It was rather contrarily believed that
epileptic seizures are only a consequence of cardiac arrhythmias,
e.g., torsades de pointes (TdP), a polymorphic ventricular
tachycardia potentially leading to cerebral hypoperfusion and
seizures (9). For KCNQ1mutation carriers, only one small family
having both, LQT syndrome and epilepsy, has been characterized
in detail (10). Thus, further investigations are required to explore
pleiotropic effects of KCNQ1 mutations on cardiac symptoms
together with epileptic seizures in patients with LQT1 syndrome.
Therefore, we markedly extended the characterization of the
Kurdish pedigree—one of the largest of a family with LQT
syndrome—aiming at the correlation between the KCNQ1dup12
mutation and the clinical manifestation of variable symptoms, in
particular syncopes, seizures, and sudden death (11).
METHODS
Study Pedigree and Clinical Phenotype
After identification of the index case (IV57) (8), the family was
systematically expanded (Supplementary Figure 1), resulting in
241 family members across five generations, for 233 of whom
a detailed medical history was available. The pedigree consisted
of 117 (48.5%) females and 124 (51.5%) males. The study was
approved by the Charité University Hospital Institutional Review
Board. All participants gave their written informed consent in
accordance with the Declaration of Helsinki.
Determination of the clinical phenotype based on interviews
with patients or close relatives, and was performed blinded
to the genetic status of the subjects. Characteristic videos
demonstrating the differences between syncope and seizures were
used to train relatives in better explanation of witnessed events,
particularly focusing on duration, aura symptoms, presence of
automatisms, focal neurologic signs, and postictal confusion.
EEG recordings (which are not the current standard of care for
the evaluation of LQT syndrome) were not available for this
Kurdish family.
ECG Analysis
Available 12-lead ECG recordings were blindly analyzed by an
experienced cardiologist. Measured QT intervals were corrected
(QTc) for heart rates between 60 and 80 bpm according to Bazett’s
formula. For heart rates faster than 80 bpm, Fridericia’s formula
was used. As repeated ECGs were not available in most cases,
LQTS was diagnosed in this study according to the Class IIa
recommendation of the European Society of Cardiology (ESC)
guidelines (12) by considering QTc times >450ms in men and
>460ms in women pathologic.
DNA Analyses
Sequence Analyses
DNA samples of 60 family members were extracted from whole
blood. Initially, mutation screening of the affected members
(IV57, V84) of the index family was performed by Sanger
sequencing for an LQT candidate gene panel. Subsequently,
whole-exome sequencing was applied for the index patient
IV57. Exonic targets were enriched using the SeqCap EZ
Human Exome Library v2.0 (Roche, NimbleGen). Sequencing
was performed on an Illumina HiSeq2000, using a 100 bp paired-
end read protocol.
Genotyping of the KCNQ1 Mutation
Large-scale genotyping of the 12-bp duplication in
exon 8 of the KCNQ1 gene (KCNQ1dup12 variation:
c.1068_1079delGCAGAAGCAGAGins(GCAGAAGCAGAG)2,
NM_000218.2, p.R360_Q361insQKQR, ENSP00000155840,
hg19) was carried out by fragment length assay (KCNQ1dup12
variation: genomic reference allele: 128 bp, mutation: 140 bp).
Polymerase chain amplification (PCR) of the KCNQ1dup12
variation was performed using flanking fluorescence-labeled
forward primer GAGCCTCCTGTCCATTCCTT and the reverse
primer ACCGCACCTGAATGAGTGA. Fragment sizes of
the biallelic PCR products were separated on ABI 3730 DNA
Analyzers and genotypes scored using GENEMAPPER version
3.7 software (Applied Biosystems, Foster City, CA, USA).
Linkage Analyses
Genome-wide linkage mapping was carried out in this
multigenerational family including 24 family members of whom
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17 members were affected by LQT (Figure 2A) and 12 members
also exhibited epileptic seizures (Figure 2B), using 5455 quality-
filtered autosomal single nucleotide polymorphisms (SNPs)
genotyped by the Illumina HumanLinkage-12 Genotyping
BeadChip (Illumina Inc., San Diego, CA, USA). Parametric
two-point and multipoint linkage analyses were performed for
an affecteds-only classification assuming an autosomal dominant
inheritance with a phenocopy rate of 1% and a mutation
prevalence of 0.1%. The linkage program MLINK (13) was
applied for parametric two-point and MERLIN for parametric
multipoint linkage analysis (14). Genotype data quality
control and data management was facilitated by the program
ALOHOMORA (15). HaploPainter (16) was used for drawing
pedigrees with haplotypes based on MERLIN calculations.
Electrophysiology
For this study, expression constructs of KCNQ1 or KCNH2 in
pCDNA3 (Invitrogen) and KCNE1 in pEGFP-N1 were used.
Mutation KCNQ1dup12 and KCNH2-R878C were introduced by
overlap-extension PCR and verified by sequencing. HEK293T
cells were maintained with 5% CO2 at 37
◦C in 45% DMEM
+ 45% F12 + 10% FCS. Cells were plated on glass coverslips
and transfected 24 h later with a constant amount of plasmid
DNA encoding wild-type or mutant KCNQ1, or a 1:1 mixture.
CD8-encoding DNA (<20% of channel DNA) was cotransfected,
allowing identification of transfected cells via CD8-detecting
beads (Dynabeads, Life Technologies). For coexpression of
KCNE1, an equal amount of DNA encoding C-terminally GFP-
tagged KCNE1 was added. In these cases, transfected cells were
identified by fluorescence microscopy. Whole-cell patch-clamp
measurements were performed with an EPC9 amplifier, operated
with PatchMaster software (HEKA Elektronik, Lambrecht,
Germany), 2 days after transfection. The bath solution contained
(in mM): 146 NaCl, 4 KCl, 2 MgCl2, 2 CaCl2, 10 HEPES (pH
7.4, NaOH). The pipette solution consisted of (in mM): 130
KCl, 2 Mg-ATP, 10 EGTA, 10 HEPES (pH 7.4, KOH). Data
were analyzed with FitMaster (HEKA Elektronik) and IgorPro
(Wavemetrics, Lake Oswego, OR, USA).
RESULTS
Family Members
The initial diagnosis of LQT syndrome was established in
the index patient IV57 (Figure 1A, arrow) when her daughter
V84 was diagnosed with a prolonged QT interval after two
syncopes. Before that, the index patient had been diagnosed of
epilepsy already for more than 20 years. In retrospect, however,
several of the “spells” in this patient during adolescence were
due to cardiac affection including palpitations, exercise-induced
syncope, presyncopal aura, short-lasting unconsciousness with
rapid reorientation, most frequently after awakening in the
morning. In adulthood, the patient suffered mainly from
generalized tonic-clonic seizures (GTCS), prolonged postictal
disorientation, enuresis and tongue bite, resulting in treatment
with carbamazepine. Treatment with β blockers resulted in
complete remission of cardiac symptoms and partial remission
of epilepsy (8).
Following this initial observation, we next analyzed
the variable clinical symptoms in one of the largest
pedigrees reported of a family with LQT syndrome
(Supplementary Figure 1). The expanded pedigree contained
241 family members across five generations. LQT syndrome
appeared in the family branches of the founder III24
(Supplementary Figure 1, arrow) with his three marriages
(III23, III25, and III27), following an autosomal-dominant
segregation pattern. Family history of sudden death was
common, 19 children died of SIDS (sudden infant death
syndrome) or SUDEP. For example, in one family tree
(IV53/IV54) 4 of 8 children died from sudden death at 0–1 years
of age.
Aiming primarily at the clinical distinction between
symptoms of cardiac syncopes vs. epileptic seizures and due
to the lack of available EEGs in this Kurdish pedigree, we
interviewed patients and relatives in a standardized way
blinded to the genetic status, supported by teaching videos
of representative syncope or seizure events. We identified 24
family members with symptoms compatible with syncope, 6 of
which passed away at 0–12 years of age. Of the remaining 18, 16
(88.9%) showed prolonged QTc intervals. Clinical assessment
revealed 24 family members with a history of GTCS including
eight deaths at 0–12 years of age. Two family members had
GTCS with normal (V51) or undetermined (V52) QTc intervals,
while all remaining 14 patients had GTCS in the context of
ECG-confirmed prolonged QTc time (LQTplus seizure trait)
(Supplementary Figure 1). However, the length of the QTc
interval in mutation carriers was not different between family
members with or without GTCS (Figure 1B) (P = 0.795, Mann
Whitney test). Also, GTCS frequency and QTc time did not
show a significant correlation (P = 0.18, R2 = 0.32, n = 7 family
members), collectively suggesting that seizures were not a result
of more severe cardiac dysfunction. All 14 patients experienced
both types of paroxysmal events, namely those related to cardiac
dysfunction (such as with profound pallor at time of spells or
exercise-related events) as well as spontaneous epileptic seizures
without antecedent cardiac symptoms (e.g., starting during rest
and followed by prolonged postictal confusion).
Mutation Screening
Initial Sanger sequencing of the most common
LQT genes in the index patient IV57 identified a
novel heterozygous 12-bp-duplication in exon 8 of
the KCNQ1 gene (KCNQ1dup12; chr11:2606477-
2606488(GCAGAAGCAGAG>(GCAGAAGCAGAG)2, hg19)
duplicating four amino acids in the carboxyterminal KCNQ1
domain (p.R360_Q361dupQKQR, NM_000218.2, hg19) (8). The
KCNQ1dup12 mutation was not detected in gnomAD in 123,136
exomes and 15,496 genomes from unrelated individuals (http://
gnomad.broadinstitute.org/). Complementary whole-exome
sequencing was carried out in the index patient IV57 affected
by the LQTplus seizure trait to search for additional mutations
in a panel of 13 genes causing cardiac arrhythmia. We were
able to confirm the KCNQ1dup12 mutation and detected a rare
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FIGURE 1 | (A) The index patient (arrow) had a long-standing history of seizures. Diagnosis of LQT syndrome was established when her daughter V84 was diagnosed
with a prolonged QT interval after two syncopes. (B) The QTc interval (mean ± SEM) was not significantly different between mutation carriers with or without
generalized tonic-clonic seizures (GTCS) (P = 0.795, Mann Whitney test).
FIGURE 2 | Genome-wide parametric multipoint linkage analyses for two LQT-trait models. (A) Linkage results for the LQT trait only identified a single major
LQT-locus at 11p15.5/KCNQ1. (B) Linkage results for the LQT-associated seizure trait revealed cosegregating susceptibility loci at 11p15.5/KCNQ1 and 10p14,
suggesting a dominant-dominant two-locus inheritance model. Blackened symbols in the pedigree denote individuals affected by the investigated LQT-trait model (A:
LQT only; B: LQT plus epileptic seizure).
heterozygous missense variant in exon 9 of KCNH2, the second
most common LQT gene (LQT2: OMIM #613688; dbSNP:
rs370393086; chr7:150647022G>A, c.2632C>T, NM_172056.2,
p.R878C, CCDS47747.1, hg19). However, protein function
prediction did not indicate a substantial functional alteration
of the amino acid substitution (p.R878C, ENST00000430723,
Polyphen: benign). Electrophysiological characterization of the
mutant channels hERG1-R878C upon heterologous expression
in HEK293T cells did not reveal functional differences compared
to wild-type hERG1 (Supplementary Figure 3). Moreover, this
rare KCNH2 missense variant (p.878C) originated from the
second wife (III25) of the KCNQ1dup12 mutation founder
(III24) and therefore its segregation was restricted to this family
branch. Although the rare KCNH2 missense variant was present
in the putative LQT phenocopy lacking the KCNQ1dup12
mutation (V85), we did not observe a familial cosegregation
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with the LQT- or LQTplus seizure trait. Thus, this rare KCNH2
missense variant or other common LQT genes are unlikely
to exert a substantial pathogenic effect on the LQT trait in
this family.
Strong Linkage Between the KCNQ1dup12
Mutation and Both the LQT Trait and
LQTplus Seizure Trait
Genotyping of the KCNQ1dup12 variation in DNA samples of 60
family members detected the always heterozygous KCNQ1dup12
mutation in 24 out of 25 genotyped family members with LQT
syndrome and all 14 genotyped family members affected by both
LQT syndrome and epileptic seizures (LQTplus seizure trait).
One family member (V85) with LQT syndrome did not carry
the KCNQ1dup12 mutation and has to be considered as putative
phenocopy. Overall, 24 out of 29KCNQ1dup12mutation carriers
were affected by an LQT syndrome, suggesting an incomplete
penetrance of about 80%. Two-point parametric linkage analysis
including 68 family members showed significant evidence for
linkage between the KCNQ1dup12 mutation and the LQT
trait (25 affected individuals) assuming an autosomal dominant
inheritance with a phenocopy rate of 1% based on the affected
individuals only (maximum LOD score: 5.21 at a recombination
fraction (θ) of 0.03, P = 4.83 × 10−7). Likewise, significant
evidence for linkage was obtained between the KCNQ1dup12
mutation and the LQTplus seizure trait in 14 affected family
members (maximum LOD score: 4.12 at KCNQ1, P = 6.63 ×
10−6). To search for other potential LQT loci, we carried out
genome-wide parametric multipoint linkage analysis in 24 family
members including 17 members with LQT. For an affecteds-only
classification and autosomal dominant mode-of-inheritance with
a presumed phenocopy rate of 1%, we found a single significant
linkage peak at the LQT1/KCNQ1 locus (multipoint LOD score:
3.25, P = 5.47× 10−5; Figure 2A).
Linkage Evidence for an LQT1/KCNQ1
Cosegregating 10p14 Risk Haplotype
Suggesting a Two-locus Inheritance Model
for the LQTplus Seizure Trait
To examine whether the LQTplus seizure trait may reflect a
variable expressivity of the KCNQ1dup12 mutation or whether
additional genetic modifier loci are involved, we carried out
genome-wide parametric multipoint linkage analyses for
an affecteds-only classification using 5455 autosomal SNPs.
For the LQTplus seizure trait (12 affected family members),
we detected two significant linkage peaks, one predominant
peak at the LQT1/KCNQ1 locus in the chromosomal region
11p15.5–p15.4 (multipoint LOD score: 3.52, P = 2.83 ×
10−5, Supplementary Figure 4A) and the second linkage
peak in the chromosomal region 10p14 (multipoint LOD
score = 3.25 at rs1033912, chr10:9592521, P = 5.47 ×
10−5, Supplementary Figure 4B) (Figure 2B). The linkage
results support a two-locus inheritance model presuming that
both the major LQT1/KCNQ1 locus and the modifier locus
on chromosome 10p14 are necessary for the coincidental
phenotypic expression of LQT and epileptic seizures in the
present family. Haplotype analysis of the chromosomal region
10p14 revealed a risk haplotype spanning 3.8Mb flanked by
the SNPs rs2671303 and rs1535976 (chr10:8074577-11850132,
hg19) (Supplementary Figure 5). Notably, all 12 family
members affected by the LQTplus seizure trait carried both
the KCNQ1dup12 mutation and the 10p14 risk haplotype. In
addition, two family members (IV38 and IV39) also carried both
the KCNQ1dup12 mutation and the 10p14 risk haplotype but
exhibited only a severely prolonged LQT interval (>500ms)
without a known history of cardiac syncopes or epileptic seizures.
This finding suggests an incomplete penetrance of approximately
80% for the two-locus model.
Electrophysiology
To assess the functional impact of the LQT mutation, the
mutation was engineered into a KCNQ1-containing plasmid
construct suited for expression in mammalian cells. As shown
in Figure 3, KCNQ1dup12-expressing cells exhibited voltage-
dependent, partially inactivating outward currents similar to
currents observed from non-transfected control cells. Cells
transfected with KCNQ1 or an equimolar mixture of wild-type
and mutant KCNQ1 DNA exhibited stronger outward currents.
Current amplitudes at the end of the depolarizations were
determined, normalized to the cell capacitance, and plotted
against voltage (Figure 3B; n = 8, each). For positive voltages,
current densities of KCNQ1-expressing cells were significantly
larger than for KCNQ1dup12-expressing cells or untransfected
cells, whereas the latter two were indistinguishable. Upon
coexpression of KCNQ1dup12, current densities were slightly
but not statistically significantly smaller than that of cells
expressing wild-type only. Since the outward currents at the
end of the depolarizations are contaminated by endogenous
channels, we also analyzed tail currents upon repolarization to
−50mV. KCNQ1-expressing cells exhibited substantial outward
tail currents, characteristic for the slow gating of KCNQ1
channels. For KCNQ1dup12 or in untransfected cells, similar
currents were barely detectable. Tail current densities from
mutant plus wild-type transfected cells were slightly but not
statistically significantly smaller than those from cells expressing
wild-type only. This finding was reproduced in a second batch of
cells with n= 15 cells each (Supplementary Figure 2), suggesting
that mutation KCNQ1dup12 does not exhibit a dominant
negative effect on KCNQ1 channels. To analyze the channel’s
voltage dependence, tail current vs. voltage data were fitted with
a Boltzmann function. The resulting voltages for half-maximal
activation (V0.5) were not significantly different between KCNQ1
(−14± 2mV) and KCNQ1 plus mutant (−14± 1mV, P= 0.76).
The corresponding voltages for e-fold change in activation (Ve)
were also indistinguishable (9.0 ± 0.5mV vs. 8.8 ± 0.6mV, P
= 0.81).
We also assessed the functional impact of mutation
KCNQ1dup12 in heteromeric KCNQ1 + KCNE1 channels,
which resemble cardiac IKs. Cells were transfected with
equal amounts of KCNQ1 DNA and KCNE1 DNA. KCNE1
was N-terminally fused to GFP allowing identification of
transfected cells. Cells transfected with KCNQ1 and KCNE1
exhibited IKs-like currents, characterized by extremely slow
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FIGURE 3 | Functional impact of the KCNQ1dup12 mutation on KCNQ1-mediated K+ currents. (A) Superimposed whole-cell current recordings evoked by the pulse
protocol shown on top. HEK293T cells were transfected with equal amounts of DNA encoding wild-type or mutant KCNQ1 or a mixture of both, as indicated.
Non-transfected cells served as controls. Current amplitude at the end of the depolarization (Iend) and maximal outward tail current (Itail) amplitudes were normalized
to the cell capacitance (Cm), averaged and plotted against voltage in (B,C), respectively. Data points are mean ± SEM (n = 8). Straight lines connect data points for
clarity.
activation upon depolarization (Figure 4A). Such types of
outward currents were not observed in cells transfected
with KCNQ1dup12 plus KCNE1 or KCNE1 alone. The latter
exhibited fast activating and partially inactivating currents
with indistinguishable current densities determined at the end
of the depolarizations (Figure 4B). Upon repolarization to
−50mV, only marginal outward currents were observed. In
contrast, KCNQ1-expressing cells exhibited robust outward
tail currents. Maximal outward tail current densities (Itail/Cm)
are plotted against voltage in Figure 4C. Cotransfection of
KCNQ1dup12 did not significantly diminish these current
densities. To analyze the voltage dependence of activation, tail
current vs. voltage data of those cells clearly differing from
those expressing KCNE1 only, were fitted with a Boltzmann
function. Resulting V0.5 and Ve data were not significantly
different between KCNQ1 plus KCNE1 expressing cells (V0.5:
30.0 ± 3.1mV and Ve: 13.7 ± 1.0mV, n = 9) and those cells
transfected with KCNQ1dup12 plus KCNQ1 plus KCNE1
(V0.5: 34.7 ± 3.4mV (P = 0.33) and Ve: 16.2 ± 0.9mV
(P = 0.88, n= 6).
DISCUSSION
While the clinical overlap between cardiac arrhythmias
and epilepsy has been well-established for LQT-associated
channelopathies related to the SCN5A and KCNH2 genes
(5, 7, 17), and epileptic seizures were found in 12% of patients
with LQT syndrome associated with KCNQ1 mutations
(4), little is known about the detailed mechanisms and
additional genetic risk factors leading to coincidental
affection of heart and brain. Experimental murine data
support the concept that KCNQ1 mutations can directly
lead to seizures, given the protein expression also in the
brain (5). A recent study used next-generation sequencing in
epilepsy patients with cardiac dysfunction or sudden death
to explore the role of already known and novel candidate
genes associated with epilepsy and SUDEP (18). Data revealed
five new variants including one copy number variant in
KCNQ1 (18).
Given that KCNQ1 gene mutations account for up to 48%
of congenital LQT syndromes (LQT1, OMIM: #192500) and
that our functional analyses confirm a deleterious functional
effect of the novel KCNQ1dup12 mutation, our sequence and
linkage analyses provide striking evidence that the mutation
plays a causative role for the LQT trait in this family. Epileptic
seizures were common in the present cohort (LQTplus seizure
trait) and frequently appeared independent of cardiac symptoms.
Since about 5–10% of LQT patients carry mutations in more
than one of the known LQT genes and typically express more
severe phenotypes with a younger age at onset (19, 20), we
addressed the question whether the LQTplus seizure trait may be
explained by variable expressivity of the KCNQ1dup12 mutation
or alternatively whether a genetic modifier locus besides KCNQ1
contributes to the coincidence of LQT and seizures. Extensive
search for additional mutations in known LQT genes detected
a rare heterozygous missense variant of KCNH2 in exon
9. KCNH2 is the second most common LQT gene, and a
loss-of-function mutation was associated with epilepsy and
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FIGURE 4 | Functional impact of the KCNQ1dup12 mutation on IKs currents. (A) Superimposed whole-cell current recordings evoked by the pulse protocol shown on
top. HEK293T cells were transfected with equal amounts of DNA encoding wild-type or mutant KCNQ1 or a mixture of both, as indicated. An equal amount of
GFP-tagged KCNE1-encoding DNA was cotransfected. Current amplitude at the end of the depolarization (Iend) and maximal outward tail current (Itail) amplitudes
were normalized to the cell capacitance (Cm), averaged and plotted against voltage in (B,C), respectively. Data points are mean ± SEM (n = 15). Straight lines
connect data points for clarity.
sudden death in a family with long QT syndrome (7). However,
protein function was not significantly different from wild-type,
and the segregation restricted to a small family branch makes
a substantial pathogenic effect on the LQT trait in this family
highly unlikely.
The manifestation of epileptic seizures also without precedent
cardiac arrhythmias in all patients with LQTplus seizures and
the absence of family members with epileptic seizures without
LQT syndrome implicate the involvement of a genetic modifier.
Indeed, genome-wide parametric multipoint linkage analyses
revealed a second linkage peak in the chromosomal region 10p14,
which was present in all 12 family members exhibiting the
LQTplus seizure trait. In turn, KCNQ1mutation carriers did not
have GTCS when lacking the cosegregating 10p14 haplotype. The
findings suggest a dominant-dominant two-locus inheritance
model in which the major LQT1/KCNQ1 locus at 11p15.5–p15.4
and the modifier locus at 10p14 act together to express the
LQTplus seizure trait (Figure 2B; Supplementary Figures 4, 5).
The 10p14 risk haplotype encompasses 24 genes, of which
the gene encoding the CUG triplet repeat, RNA-binding
protein 2 (gene symbol: CELF2, chr10:10838851-11378674,
Entrez 10659, hg19) represents a high-ranking candidate gene
for the phenotypic expression of LQT-associated seizures.
CELF2 is part of CUG-BP, Elav-like family (CELF1-6) and is
involved in the regulation of alternative RNA splicing in the
brain (21). Mice deficient for Celf4 exhibit a complex seizure
disorder that includes both convulsive and non-convulsive
seizures resulting from an increased neuronal excitation due to
aberrant Nav1.6 (Scn8a) sodium channel activity (22). Likewise,
haploinsufficiency of human CELF4 has been implicated to cause
an impaired neurodevelopment with febrile seizures in a patient
with a truncated CELF4 gene due to a de novo translocation
(23). Together, these findings support an involvement of
CELF proteins in the regulation of neuronal excitability and
epileptogenesis. Notably, whole-exome sequencing in the index
patient IV57 did not identify any deleterious coding mutation
of the CELF2 gene or other genes located on the risk haplotype
on chromosome 10p14. However, mutations in the non-coding
sequences of the CELF2 gene may have been missed by targeted
sequencing of theCELF2 exons and exon-intron boundaries only.
Recurrent events in the patients of our cohort resulted from
two different etiologies. First, they had LQT-related cardiac
dysfunctions such as ventricular tachyarrhythmia or syncope.
Secondary brain symptoms may be misdiagnosed as epileptic
seizures but in fact result from hypoxia-triggered seizures.
According to the diagnostic manual of the ILAE’s (International
League Against Epilepsy) commission on classification and
terminology, these paroxysmal events are classified as epilepsy
imitators. We reduced the common difficulties in clinical
distinction between epileptic seizures and cardiac syncopes
by use of representative videos and a detailed history paying
particular attention to symptoms which help to distinguish
both conditions (such as profound pallor at time of seizures or
exercise-related events pointing to cardiac disease).
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Second, the family members with LQT-associated seizures
exhibited a genetic epilepsy related to the major LQT1/KCNQ1
locus and the cosegregating 10p14 modifier locus, independent
of cardiac dysfunction. Thus, the KCNQ1dup12 mutation
represented a susceptibility gene not leading to GTCS alone,
but caused seizures in combination with the 10p14 risk allele in
this LQT1 family. This notion is further supported by clinical
observations, including witnessed prolonged grand mal status of
20–30min in one woman or witnessed GTCS in another by an
epileptologist leading to treatment and assessment for epilepsy
surgery. It is also supported by equal QTc intervals in mutation
carriers with and without GTCS, suggesting that more severe
heart disease is not the trigger for seizures.
Electrophysiological recordings with the here described
KCNQ1dup12 mutation exhibited no channel activity of the
mutant. In the absence or presence of KCNE1 subunits,
we did not find substantial KCNQ1- or IKs-like currents
types significantly differing in current densities between
KCNQ1dup12-transfected cells and their respective controls.
This may be explained either by a lack of functional mutant
protein, e.g., due to an impaired trafficking, or a complete loss
of function, induced by the mutation. In the absence of further
evidence for presence of the mutant protein in the plasma
membrane, we cannot distinguish between these possibilities.
Nevertheless, our data clearly indicate that the mutation does
not exhibit a dominant negative effect. Neither with nor
without coexpression of KCNE1, expression of the mutant
significantly suppressed functional wild-type KCNQ1. Since
in both cases coexpression of KCNQ1dup12 did not affect the
voltage dependence of the channels, it appears more likely that
the mutation impairs functional expression and thus the protein
is not incorporated into a heteromeric channel tetramer.
Taken together, we electrophysiologically and genetically
characterized a novel KCNQ1 loss-of-function mutation in
the largest family with LQT1 syndrome reported so far,
demonstrating the causative role of the KCNQ1dup12 mutation
for the LQT trait. In addition, we established a genetic two-
locus model explaining the coincidental manifestation of LQT-
associated epileptic seizures, based on a cosegregation of the
KCNQ1dup12 mutation with a strong genetic modifier located
in the chromosomal region 10p14. Our present findings provide
novel insights into how KCNQ1 mutations in LQT patients can
lead to both, cardiac dysfunction with arrhythmias or syncope
and increased cerebral excitability with epileptic seizures. They
emphasize complex genetic models underlying genetic epilepsies
beyond rare single gene effects to explain the remarkably variable
phenotypic expressivity across familial epilepsies.
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